Categories Earnings, Retail

Activist investor wants Campbell Soup sale, but who will buy?

Dan Loeb, manager of Third Point hedge fund, along with another shareholder is pushing for the sale of Campbell Soup (CPB). Third Point holds a 5.6% stake in Campbell, which is currently undergoing a strategic review. Loeb and the other shareholder, George Strawbridge, hold a combined stake of over 8% in Campbell.

It is believed the best outcome of the strategic review would be a sale, but in order to sell the company, Third Point needs to get the support of the founding family, whose members hold a combined stake of 41%. The family is divided in its opinion on the sale of Campbell. The company plans to reveal more details at the announcement of its fourth quarter results, which is due at the end of this month.

Campbell, which held a strong position once, has lost a major chunk of its value over the years

One aspect to watch out for would be whether the family will agree to a sale but an equally interesting point is whether Campbell can get a buyer. Campbell, which held a strong position once, has been struggling for a while and has lost a major chunk of its value over the years. Kraft Heinz, which was touted as a possible suitor recently, does not appear to have plans on scooping up Campbell.

Packaged foods companies like Campbell Soup are facing tough competition from major retailers like Amazon (AMZN) and Walmart (WMT). Campbell, which reported a loss for its third quarter and saw the abrupt exit of its CEO at the time, has been struggling to keep up in the industry. The company is seeing a slowdown in its soup business while the fresh foods business is posting losses.

Campbell also appears to be facing issues with the integration of the Snyder’s-Lance business. Some analysts have suggested that a spin-off of the company’s snacks business, which is doing well, would be a good strategy. Campbell’s stock is down over 12% so far this year.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top